within Pharmacolibrary.Drugs.ATC.C;

model C10BA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.0002,
    adminDuration  = 600,
    adminMass      = 180 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10BA10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bempedoic acid and ezetimibe is a fixed-dose combination medication used to lower LDL cholesterol in adults with primary hypercholesterolemia or mixed dyslipidemia. Bempedoic acid inhibits ATP-citrate lyase, reducing cholesterol synthesis in the liver, while ezetimibe inhibits intestinal absorption of cholesterol. This combination is approved as an adjunct to diet in adults in combination with other lipid-lowering therapies.</p><h4>Pharmacokinetics</h4><p>Estimated PK parameters for healthy adult volunteers following oral administration as per available product information for the fixed dose combination.</p><h4>References</h4><ol><li><p>Saeed, A, &amp; Ballantyne, CM (2018). Bempedoic Acid (ETC-1002): A Current Review. <i>Cardiology clinics</i> 36(2) 257–264. DOI:<a href=\"https://doi.org/10.1016/j.ccl.2017.12.007\">10.1016/j.ccl.2017.12.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29609755/\">https://pubmed.ncbi.nlm.nih.gov/29609755</a></p></li><li><p>Tomlinson, B, et al., &amp; Lam, CWK (2020). Pharmacokinetics of current and emerging treatments for hypercholesterolemia. <i>Expert opinion on drug metabolism &amp; toxicology</i> 16(5) 371–385. DOI:<a href=\"https://doi.org/10.1080/17425255.2020.1749261\">10.1080/17425255.2020.1749261</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32223657/\">https://pubmed.ncbi.nlm.nih.gov/32223657</a></p></li><li><p>Scheen, AJ, et al., &amp; Wallemacq, C (2022). [Bempedoïc acid, new cholesterol-lowering drug]. <i>Revue medicale de Liege</i> 77(2) 124–131. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35143133/\">https://pubmed.ncbi.nlm.nih.gov/35143133</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10BA10;
